The orbital research economy will be won on standards
I watched SpaceX go public with the same mixed feeling I suspect a lot of people in this industry did, relief, mostly. The largest listing in history just told the market, in the blunt language it actually understands, that space is a real asset class and not a rich man’s hobby. Good, this was needed! […] The post The orbital research economy will be won on standards appeared first on EU-Startups…
The space industry's race for the largest IPO in history has highlighted the growing importance of space in the pharmaceutical industry. While microgravity offers unique advantages for pharmaceutical research, creating standards is crucial to unlock the full potential of this emerging sector. Successful pharmaceutical research in space requires reproducible, validated results that can be compared to terrestrial models.
Regulators rely on established standards like GLP, GxP, ICH guidelines, USP monographs, ISO/IEC 17025, and assay-validation norms to ensure data quality and consistency. For microgravity research to gain traction in the pharmaceutical industry, it must adhere to these standards, allowing researchers to compare results with existing data and build trust.
The first team to successfully implement these standards in their space-based research will establish a valuable product that can be easily integrated into existing datasets, gaining a significant advantage in the market.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
